Rep. Steve Cohen Sells Emergent BioSolutions Inc. (NYSE:EBS) Shares

Representative Steve Cohen (D-Tennessee) recently sold shares of Emergent BioSolutions Inc. (NYSE:EBS). In a filing disclosed on January 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Emergent BioSolutions stock on December 11th. The trade occurred in the Representative’s “STEPHENS SEP IRA” account.

Representative Steve Cohen also recently made the following trade(s):

• Sold $15,001 – $50,000 in shares of Host Hotels & Resorts (NASDAQ:HST) on 12/11/2024.

Emergent BioSolutions Stock Down 0.4 %

Shares of NYSE EBS opened at $9.37 on Wednesday. The company’s 50 day moving average price is $9.36 and its 200-day moving average price is $9.17. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.47 and a current ratio of 2.88. Emergent BioSolutions Inc. has a 52-week low of $1.42 and a 52-week high of $15.10. The company has a market capitalization of $507.70 million, a P/E ratio of -2.29 and a beta of 1.60.

Hedge Funds Weigh In On Emergent BioSolutions

Institutional investors have recently modified their holdings of the company. Meeder Asset Management Inc. acquired a new position in shares of Emergent BioSolutions during the second quarter valued at about $41,000. Vanguard Personalized Indexing Management LLC bought a new stake in Emergent BioSolutions during the 2nd quarter worth approximately $93,000. Stifel Financial Corp purchased a new stake in shares of Emergent BioSolutions in the third quarter worth approximately $96,000. Morse Asset Management Inc bought a new position in shares of Emergent BioSolutions in the second quarter valued at approximately $97,000. Finally, FORA Capital LLC purchased a new position in shares of Emergent BioSolutions during the third quarter valued at approximately $103,000. 78.40% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EBS has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a report on Friday, January 10th. StockNews.com raised Emergent BioSolutions from a “hold” rating to a “buy” rating in a research note on Tuesday. Finally, Benchmark raised their price objective on shares of Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

About Representative Cohen

Steve Cohen (Democratic Party) is a member of the U.S. House, representing Tennessee’s 9th Congressional District. He assumed office on January 3, 2007. His current term ends on January 3, 2025. Cohen (Democratic Party) is running for re-election to the U.S. House to represent Tennessee’s 9th Congressional District. He declared candidacy for the Democratic primary scheduled on August 1, 2024. He represented District 30 of the Tennessee State Senate from 1983-2006. As a child, Cohen contracted polio. Cohen filed to run for his first elected office the same day that he first registered to vote. Cohen earned a bachelor’s degree from Vanderbilt and a J.D. from the University of Memphis School of Law. Prior to his election to the U.S. House, Cohen was a member of the Tennessee State Senate.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.